New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology
January 15, 2019:
Nymox Pharmaceutical Corporation reports today that a new peer review article has been published in Therapeutic Advances in Urology.
December 19, 2018:
Following the Nymox Annual General Meeting yesterday (December 18, 2018), Nymox management discussed many significant 2018 events and commented on key operational milestones coming up in 2019.
October 11, 2018:
Following many shareholder enquiries in recent weeks Nymox Pharmaceutical Corporation is pleased to provide shareholders with a brief update on its core activities.
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
October 9, 2018:
Nymox Pharmaceutical Corporation is pleased to announce today important new long-term clinical trial results from the Company’s 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer.
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
October 3, 2018:
Nymox Pharmaceutical Corporation reported today that after long-term safety assessments of repeated Fexapotide Triflutate (FT) intraprostatic injections, there have been no identifiable risks or serious side effects or adverse events identified associated or linked with the drug.
July 2, 2018:
Nymox Pharmaceutical Corporation announced today that following the recently announced increased manufacturing capabilities, the Company has formally decided to expand its European marketing plans for Fexapotide Triflutate (FT) to all countries in the European Community.
June 7, 2018:
Nymox Pharmaceutical Corporation is pleased to report that manufacturing scale-up milestones have been reached for the Company’s lead compound Fexapotide Triflutate (FT).
Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco
May 22, 2018:
Nymox Pharmaceutical Corporation is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend.
May 11, 2018:
Nymox Pharmaceutical Corporation is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology, a highly respected and authoritative urologic professional community, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions.
May 7, 2018:
Nymox Pharmaceutical Corporation is pleased to announce that it has initiated the process of relocating the Company Headquarters from Nassau, Bahamas to Zug in Switzerland.